Sanofi EBIT Margin 2010-2023 | SNY
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Sanofi (SNY) over the last 10 years. The current EBIT profit margin for Sanofi as of December 31, 2023 is .
| Sanofi EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$50.27B |
$9.59B |
19.08% |
| 2023-09-30 |
$49.01B |
$10.30B |
21.03% |
| 2023-06-30 |
$48.42B |
$11.11B |
22.95% |
| 2023-03-31 |
$48.20B |
$10.71B |
22.21% |
| 2022-12-31 |
$47.82B |
$10.72B |
22.42% |
| 2022-09-30 |
$48.72B |
$12.21B |
25.07% |
| 2022-03-31 |
$34.76B |
$8.80B |
25.31% |
| 2021-09-30 |
$35.03B |
$9.03B |
25.79% |
| 2021-03-31 |
$43.57B |
$10.31B |
23.66% |
| 2020-09-30 |
$42.75B |
$9.32B |
21.80% |
| 2020-03-31 |
$41.19B |
$7.94B |
19.28% |
| 2019-09-30 |
$41.49B |
$6.79B |
16.37% |
| 2019-03-31 |
$41.50B |
$6.71B |
16.17% |
| 2018-03-31 |
$41.43B |
$6.77B |
16.33% |
| 2017-12-31 |
$40.92B |
$7.07B |
17.27% |
| 2017-09-30 |
$40.25B |
$7.72B |
19.19% |
| 2017-06-30 |
$39.59B |
$8.01B |
20.24% |
| 2017-03-31 |
$39.14B |
$8.14B |
20.79% |
| 2016-12-31 |
$38.41B |
$7.59B |
19.77% |
| 2016-09-30 |
$39.27B |
$8.06B |
20.52% |
| 2016-06-30 |
$39.37B |
$7.47B |
18.97% |
| 2016-03-31 |
$41.16B |
$7.72B |
18.76% |
| 2015-09-30 |
$42.97B |
$7.96B |
18.53% |
| 2015-06-30 |
$43.92B |
$7.84B |
17.84% |
| 2014-06-30 |
$44.70B |
$8.29B |
18.54% |
| 2013-06-30 |
$45.22B |
$8.36B |
18.48% |
| 2012-06-30 |
$46.75B |
$9.00B |
19.24% |
| 2012-03-31 |
$47.10B |
$8.41B |
17.86% |
| 2011-12-31 |
$47.27B |
$8.89B |
18.80% |
| 2011-09-30 |
$45.65B |
$8.20B |
17.97% |
| 2011-06-30 |
$44.35B |
$8.97B |
20.23% |
| 2011-03-31 |
$42.93B |
$10.32B |
24.03% |
| 2010-12-31 |
$41.26B |
$9.22B |
22.33% |
| 2010-09-30 |
$41.28B |
$8.91B |
21.59% |
| 2010-06-30 |
$41.42B |
$8.83B |
21.33% |
| 2010-03-31 |
$41.35B |
$8.80B |
21.28% |
| 2009-12-31 |
$40.79B |
$8.81B |
21.60% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$120.637B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
